278 related articles for article (PubMed ID: 31649026)
1. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
[TBL] [Abstract][Full Text] [Related]
2. mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells.
Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
Mol Cancer Ther; 2018 Dec; 17(12):2676-2688. PubMed ID: 30282812
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis.
Mak JP; Man WY; Ma HT; Poon RY
Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733
[TBL] [Abstract][Full Text] [Related]
4. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
[TBL] [Abstract][Full Text] [Related]
5. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Goss KL; Gordon DJ
Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498
[TBL] [Abstract][Full Text] [Related]
6. The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors.
Goss KL; Koppenhafer SL; Waters T; Terry WW; Wen KK; Wu M; Ostergaard J; Gordon PM; Gordon DJ
Oncogene; 2021 Jan; 40(3):564-577. PubMed ID: 33191406
[TBL] [Abstract][Full Text] [Related]
7. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
9. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.
Zhang YW; Jones TL; Martin SE; Caplen NJ; Pommier Y
J Biol Chem; 2009 Jul; 284(27):18085-95. PubMed ID: 19416980
[TBL] [Abstract][Full Text] [Related]
10. Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction.
Rieunier G; Wu X; Harris LE; Mills JV; Nandakumar A; Colling L; Seraia E; Hatch SB; Ebner DV; Folkes LK; Weyer-Czernilofsky U; Bogenrieder T; Ryan AJ; Macaulay VM
Cancer Res; 2021 Apr; 81(8):2128-2141. PubMed ID: 33509941
[TBL] [Abstract][Full Text] [Related]
11. A MYBL2 complex for RRM2 transactivation and the synthetic effect of MYBL2 knockdown with WEE1 inhibition against colorectal cancer.
Liu Q; Guo L; Qi H; Lou M; Wang R; Hai B; Xu K; Zhu L; Ding Y; Li C; Xie L; Shen J; Xiang X; Shao J
Cell Death Dis; 2021 Jul; 12(7):683. PubMed ID: 34234118
[TBL] [Abstract][Full Text] [Related]
12. HPV31 utilizes the ATR-Chk1 pathway to maintain elevated RRM2 levels and a replication-competent environment in differentiating Keratinocytes.
Anacker DC; Aloor HL; Shepard CN; Lenzi GM; Johnson BA; Kim B; Moody CA
Virology; 2016 Dec; 499():383-396. PubMed ID: 27764728
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
[TBL] [Abstract][Full Text] [Related]
14. Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress.
Saini P; Li Y; Dobbelstein M
Oncotarget; 2015 May; 6(15):13072-87. PubMed ID: 25965828
[TBL] [Abstract][Full Text] [Related]
15. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
Ngoi NY; Sundararajan V; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of ATR inhibitors as single agents in Ewing sarcoma.
Nieto-Soler M; Morgado-Palacin I; Lafarga V; Lecona E; Murga M; Callen E; Azorin D; Alonso J; Lopez-Contreras AJ; Nussenzweig A; Fernandez-Capetillo O
Oncotarget; 2016 Sep; 7(37):58759-58767. PubMed ID: 27577084
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis.
Bukhari AB; Lewis CW; Pearce JJ; Luong D; Chan GK; Gamper AM
J Clin Invest; 2019 Mar; 129(3):1329-1344. PubMed ID: 30645202
[TBL] [Abstract][Full Text] [Related]
18. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y
J Virol; 2019 May; 93(9):. PubMed ID: 30787154
[TBL] [Abstract][Full Text] [Related]
19. Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response.
Maude SL; Enders GH
Cancer Res; 2005 Feb; 65(3):780-6. PubMed ID: 15705874
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of cells to ATR and CHK1 inhibitors requires hyperactivation of CDK2 rather than endogenous replication stress or ATM dysfunction.
Ditano JP; Donahue KL; Tafe LJ; McCleery CF; Eastman A
Sci Rep; 2021 Mar; 11(1):7077. PubMed ID: 33782497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]